News · 26 weeks44+17%
2025-12-142026-06-07
Mix2290d
- SEC Filings8(36%)
- Other6(27%)
- Insider5(23%)
- Leadership1(5%)
- Earnings1(5%)
- Analyst1(5%)
Latest news
25 items- SECAccuray Incorporated filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure8-K - ACCURAY INC (0001138723) (Filer)
- INSIDERSEC Form 4 filed by SVP, Chief Commercial Officer Miele Paul Michael4 - ACCURAY INC (0001138723) (Issuer)
- SECSEC Form SD filed by Accuray IncorporatedSD - ACCURAY INC (0001138723) (Filer)
- PRAccuray Incorporated Reports Inducement Award Under NASDAQ Listing RulesMADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer. As material inducements to Mr. Miele and Mr. Shin joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee approved the granting of equity inducement awards to each of Mr. Miele and Mr. Shin, in each case effective as of May 29, 2026 (collectively, the "Inducement Awar
- SECSEC Form S-8 filed by Accuray IncorporatedS-8 - ACCURAY INC (0001138723) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Accuray IncorporatedSCHEDULE 13D/A - ACCURAY INC (0001138723) (Subject)
- INSIDERSEC Form 4 filed by Large owner Tcw Group Inc4 - ACCURAY INC (0001138723) (Issuer)
- PRAccuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with CancerMADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. This agreement builds on longstanding shared history of partnership between Accuray and the school to develop precision radiation therapy technologies using imaging to precisely deliver dose sculpting for cancer treatments. This newest collaboration will support clinical research, education and training, and the development of adaptive therapies that help empower medical care teams to co
- ANALYSTAccuray downgraded by BTIG ResearchBTIG Research downgraded Accuray from Buy to Neutral
- SECSEC Form 10-Q filed by Accuray Incorporated10-Q - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- PRAccuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), c
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Accuray IncorporatedSCHEDULE 13D/A - ACCURAY INC (0001138723) (Subject)
- INSIDERSEC Form 3 filed by new insider Tcw Group Inc3 - ACCURAY INC (0001138723) (Issuer)
- INSIDERSEC Form 3 filed by new insider Miele Paul Michael3 - ACCURAY INC (0001138723) (Issuer)
- SECAccuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- PRAccuray Appoints Paul Miele as Senior Vice President and Chief Commercial OfficerMADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform
- INSIDERSEC Form 4 filed by Chalke Sandeep4 - ACCURAY INC (0001138723) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Accuray IncorporatedSCHEDULE 13G/A - ACCURAY INC (0001138723) (Subject)
- SECAccuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- INSIDERSVP, Chief Operations Officer Peralta Leonel converted options into 83,723 shares and covered exercise/tax liability with 28,969 shares (SEC Form 4)4 - ACCURAY INC (0001138723) (Issuer)
- SECSEC Form EFFECT filed by Accuray IncorporatedEFFECT - ACCURAY INC (0001138723) (Filer)
- SECSEC Form 424B3 filed by Accuray Incorporated424B3 - ACCURAY INC (0001138723) (Filer)
ARAY FAQ
7 questionsWhat does Accuray Incorporated do?
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of...Where does ARAY stock trade?
Accuray Incorporated (ARAY) is listed on NASDAQ.What sector and industry is ARAY in?
Accuray Incorporated operates in the Health Care sector, Medical/Dental Instruments industry.When did Accuray Incorporated go public?
Accuray Incorporated (ARAY) completed its IPO in 2007.What are analysts saying about ARAY?
Accuray Incorporated has had 4 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2026-05-07. Recent price targets range from $750.00 to $900.00.What companies are similar to ARAY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare ARAY side-by-side with any of them on Quantisnow.How can I track ARAY on Quantisnow?
Quantisnow aggregates Accuray Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARAY to receive live email and push alerts on every new disclosure.